Is Zentalis Pharmaceuticals Inc (ZNTL) Stock About to Get Hot Thursday?

The market has been down on Zentalis Pharmaceuticals Inc (ZNTL) stock recently. ZNTL gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Zentalis Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ZNTL!

See Full ZNTL Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ZNTL Stock Today?

Zentalis Pharmaceuticals Inc (ZNTL) stock is down -4.2% while the S&P 500 has gained 0.11% as of 12:36 PM on Thursday, Feb 29. ZNTL has fallen -$0.65 from the previous closing price of $15.49 on volume of 270,668 shares. Over the past year the S&P 500 is higher by 27.83% while ZNTL has fallen -21.61%. ZNTL lost -$4.47 per share in the over the last 12 months. To screen for more stocks like Zentalis Pharmaceuticals Inc click here.

More About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Click Here to get the full Stock Report for Zentalis Pharmaceuticals Inc stock.